Mendus presenterar uppdaterad data från ALISON-studien med vididencel i äggstockscancer vid SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Pressmeddelande Stockholm, 6 november 2023 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag publiceringen av uppdaterade...
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
November 04, 2023 12:00 ET
|
Medigene AG
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
November 03, 2023 14:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023 12:01 ET
|
HOOKIPA Pharma Inc.
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting
November 03, 2023 03:58 ET
|
Glycotope
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a...
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing
October 31, 2023 09:00 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
October 31, 2023 09:00 ET
|
Akoya Biosciences, Inc.
Spatial Biology 2.0 solutions enable discovery and translational workflows at an unprecedented speed and scale Global network of CROs providing Akoya’s spatial phenotyping solutions will also exhibit...
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
October 30, 2023 06:41 ET
|
ImCheck Therapeutics SAS
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting Marseille, France, October 30, 2023 – ImCheck...
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing
October 23, 2023 03:00 ET
|
Medigene AG
Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell...